O4 Tivozanib hydrochloride versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from the Phase III randomized, open-label, multicenter TIVO-1 trial

✍ Scribed by Motzer, R.; Nosov, D.; Eisen, T.; Lipatov, O.; Tomczak, P.; Lyulko, O.; Harza, M.; Alekseev, B.Y.; Sternberg, C.N.; Szczylik, C.; Jinga, V.; Zhang, J.; Strahs, A.; Esteves, B.; Slichenmyer, W.; Berkenblit, A.; Hutson, T.E.

• Book ID: 122618250
• Publisher: Elsevier Science
• Year: 2012
• Tongue: English
• Weight: 57 KB
• Volume: 11
• Category: Article
• ISSN: 1569-9056
• DOI: 10.1016/S1569-9056(13)60373-5